Peter W. Janes

145 Studley Road
Heidelberg, VIC 3084, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.

A Phase I and Biodistribution Study of Ifabotuzumab, a Humanized Agonistic EphA3-Targeted Antibody, in Patients with Recurrent Glioblastoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 04, 2025

ADAM10 Knockout from Human Glioblastoma and Colon Cancer Cells Modulates Diverse Signalling Networks and Inhibits Tumour Growth In Vivo.

ADAM10 Knockout from Human Glioblastoma and Colon Cancer Cells Modulates Diverse Signalling Networks and Inhibits Tumour Growth In Vivo.

Journal: International journal of molecular sciences
Published: September 10, 2025

ADAM Proteases in Cancer: Biological Roles, Therapeutic Challenges, and Emerging Opportunities.

ADAM Proteases in Cancer: Biological Roles, Therapeutic Challenges, and Emerging Opportunities.

Journal: Cancers
Published: April 15, 2025

Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2.

Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2.

Journal: Molecular cancer therapeutics
Published: July 15, 2024

Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects.

Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects.

Journal: Journal of biomedical science
Published: April 05, 2024

An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy.

An Anti-VEGF-B Antibody Reduces Abnormal Tumor Vasculature and Enhances the Effects of Chemotherapy.

Journal: Cancers
Published: April 03, 2024

Co-clustering of EphB6 and ephrinB1 in trans restrains cancer cell invasion.

Co-clustering of EphB6 and ephrinB1 in trans restrains cancer cell invasion.

Journal: Communications biology
Published: February 20, 2024

Inhibition of EphA3 Expression in Tumour Stromal Cells Suppresses Tumour Growth and Progression.

Inhibition of EphA3 Expression in Tumour Stromal Cells Suppresses Tumour Growth and Progression.

Journal: Cancers
Published: August 03, 2023

Fully human monoclonal antibody targeting activated ADAM10 on colorectal cancer cells.

Fully human monoclonal antibody targeting activated ADAM10 on colorectal cancer cells.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 09, 2023

Eph Receptors in Cancer.

Eph Receptors in Cancer.

Journal: Biomedicines
Published: December 14, 2022

Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours.

Preferential Antibody and Drug Conjugate Targeting of the ADAM10 Metalloprotease in Tumours.

Journal: Cancers
Published: May 02, 2022

The intracellular domains of the EphB6 and EphA10 receptor tyrosine pseudokinases function as dynamic signalling hubs.

The intracellular domains of the EphB6 and EphA10 receptor tyrosine pseudokinases function as dynamic signalling hubs.

Journal: The Biochemical journal
Published: July 27, 2021
Showing 1-12 of 27

Last Updated: 09/26/2026